PASSAGE BIO, INC. Operating Lease Liability
PASSAGE BIO, INC. (PASG) had Operating Lease Liability of $5.75 million as of 2026-03-31, per its S-4 filed 2026-07-21.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-09-03
- 2026-03-31: Operating Lease, Liability $5.75M.
- 2025-12-31: Operating Lease, Liability $24.01M.
- 2025-09-30: Operating Lease, Liability $24.34M.
- 2025-06-30: Operating Lease, Liability $24.73M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-03-31 | $5.75M S-4 · filed 2026-07-21 |
| 2025-12-31 | $24.01M S-4/A · filed 2026-09-03 |
| 2025-09-30 | $24.34M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $24.73M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $25.12M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $25.48M 10-K · filed 2025-03-04 |
| 2024-09-30 | $25.82M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $26.15M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $26.48M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $26.29M 10-K · filed 2024-03-04 |
| 2023-09-30 | $26.52M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $26.74M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $26.95M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $27.11M 10-K · filed 2023-03-06 |
| 2022-09-30 | $27.29M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $27.47M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $27.55M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |